Claims for Patent: 8,399,496

Summary for Patent: 8,399,496

Title:	Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
Abstract:	A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.
Inventor(s):	Montgomery; Alan Bruce (Seattle, WA), Keller; Manfred (Munchen, DE), Lintz; Frank-Christophe (Starnberg, DE)
Assignee:	Gilead Sciences, Inc. (Foster City, CA)
Application Number:	12/229,425
Patent Claims:	1. An inhalable composition comprising astreonam lysinate and a pharmaceutically acceptable diluent. 2. A method for administering by inhalation aztreonam lysinate comprising administering a composition comprising aztreonam lysinate and a pharmaceutically acceptable diluent. 3. The method according to claim 2, wherein the diluent is saline. 4. The method according to claim 2, wherein said composition comprises from about 1 to about 250 mg of aztreonam lysinate dissolved in about 1 to about 5 mL of saline solution containing from about 0.1 to about 0.9%, w/v, of sodium chloride. 5. The method according to claim 2, wherein said composition is delivered by a nebulizer. 6. The method according to claim 5, wherein said nebulizer is an atomizing jet, ultrasonic, electronic or vibrating porous plate nebulizer. 7. The method according to claim 2, wherein said composition consists of 75 mg of aztreonam and 47 mg of lysine per 1 mL of saline. 8. A method for improving pulmonary function in a patient with cystic fibrosis, said method comprising administering by inhalation aztreonam lysinate to said patient. 9. The method according to claim 8, wherein said step of administering comprises administering a composition comprising aztreonam lysinate and a pharmaceutically acceptable diluent. 10. The method according to claim 9, wherein the diluent is saline. 11. The method according to claim 9, wherein said composition comprises from about 1 to about 250 mg of aztreonam lysinate dissolved in about 1 to about 5 mL of saline solution containing from about 0.1 to about 0.9%, w/v, of sodium chloride. 12. The method according to claim 9, wherein said composition is delivered by a nebulizer. 13. The method according to claim 12, wherein said nebulizer is an atomizing jet, ultrasonic, electronic or vibrating porous plate nebulizer. 14. The method according to claim 11, wherein said composition consists of 75 mg of aztreonam and 47 mg of lysine per 1 mL of saline. 15. A method for treating an infection caused by gram-negative bacteria in a patient with cystic fibrosis, said method comprising administering by inhalation an aztreonam lysinate composition to said patient, wherein said composition comprises from about 1 to about 250 mg of aztreonam lysinate dissolved in about 1 to about 5 mL of saline solution containing from about 0.1 to about 0.9%. w/v, of sodium chloride. 16. The method according to claim 15, wherein said composition consists of sodium chloride composition consists of 75 mg of aztreonam and 47 mg of lysine per 1 mL of saline. 17. A method according to claim 15, wherein said composition is delivered by a nebulizer. 18. The method according to claim 17, wherein said nebulizer is an atomizing jet, ultrasonic, electronic or vibrating porous plate nebulizer. 19. A method for treating an infection caused by gram-negative bacteria in a patient with bronchiectasis, said method comprising administering by inhalation aztreonam lysinate to said patient 20. The method according to claim 19, wherein said step of administering comprises administering a composition comprising aztreonam lysinate and a pharmaceutically acceptable diluent. 21. The method according to claim 20, wherein said composition comprises from about 1 to about 250 mg of aztreonam lysinate dissolved in about 1 to about 5 mL of saline solution containing from about 0.1 to about 0.9%, w/v, of sodium chloride. 22. The method according to claim 21, wherein said composition is delivered by a nebulizer. 23. The method according to claim 22, wherein said nebulizer is an atomizing jet, ultrasonic, electronic, or vibrating porous plate nebulizer. 24. The method according to claim 21, wherein said composition consists of 75 mg of aztreonam and 47 mg of lysine per 1 mL of saline.